IgAN: Pathogenesis and pathophysiology | With Dr Richard Lafayette

https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/f0/51/52/f051520c-ad96-4d82-b18a-4941bfc1bcbb/mza_1630558881021850882.jpg/600x600bb.jpg

Nephrology Knowledge into Practice Podcast

8 episodes

1 week ago

A summary of new trial data, guideline recommendations and expert opinion across kidney care, run by Nephrology Knowledge into Practice (https://nephrology.knowledgeintopractice.com), featuring interviews with leading experts from across the globe. This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes.

Medicine

Health & Fitness

RSS

All content for Nephrology Knowledge into Practice Podcast is the property of Nephrology Knowledge into Practice Podcast and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo400/22384965/22384965-1646135246312-795c8c4e26184.jpg

IgAN: Pathogenesis and pathophysiology | With Dr Richard Lafayette

Nephrology Knowledge into Practice Podcast

14 minutes

3 years ago

IgAN: Pathogenesis and pathophysiology | With Dr Richard Lafayette

IgA nephropathy (IgAN) is a leading cause of chronic kidney disease and the most common glomerular disease worldwide. But its pathogenesis has not yet been fully elucidated, leaving some questions so far unanswered. Join Dr Richard Lafayette for an overview of our current understanding of how this disease develops and presents.

By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References:

1. Penfold RS, Prendecki M, McAdoo S, Tam FW. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018 Apr 12;11:137-148.

2. Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4): 677-686. doi: 10.2215/CJN.07420716

3. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276.

4. Chang S, Li X-K. The role of immune modulation in pathogenesis of IGA nephropathy. Front Med.7:92.

Disclosures:

Dr Richard Lafayette declares the following:

Research: Travere, Omeros, Calliditas, Vera, Otsuka/Visterra

Consulting: Travere, Omeros, Calliditas, Vera, Otsuka/Visterra

All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME and validated by an independent steering committee; Travere Therapeutics has had no influence on the content of this education.